In addition to therapeutic proteins, new biological targets include gene therapy, viral vectors, mRNA, and whole cells.  The new modalities rely on critical raw material delivery systems such as pDNA, and viral vectors such as AAV, adenovirus, lentivirus, retrovirus, exosomes, oncolytic virus, and virus-based vaccines.​ Emerging modalities focus on whole cell bioprocessing such as cultured meat, and therapies based on stem cells, cell therapy, and T cells.

Repligen solutions help overcome key challenges in the development and production of these modalities into a new class of drugs. Repligen also offers hands-on process and implementation consultation from global Field Applications Specialists, and recognized gene therapy, oncolytic and vaccines industry experts.​

Speak to an expert

Antibodies, rProteins

Therapeutic proteins treat a wide variety of clinical indications, including cancers, autoimmunity, inflammation, infectious disease and genetic disorders. Applications include the bioprocessing of monoclonal antibodies, antibody fragments, Fc and albumin fusions, blood factors, and protein-based vaccines.

Viral Vectors

Adeno-associated virus (AAV) is the most common viral vector used in gene therapy bioprocessing. Other viral vectors include adenovirus, lentivirus, retrovirus, oncolytic virus, and virus-based vaccines.


 With the proven success of mRNA-based vaccines in addressing the COVID-19 pandemic, mRNA technology is at the forefront of transforming the world of medicine. Clinical trials are ongoing to develop both vaccines and therapies to treat infectious diseases and even cancer. 


Plasmid DNA (pDNA) is a critical raw material delivery template for the development and production of mRNA or viral vectors such as lentivirus and adeno-associated virus (AAV) vectors.

Emerging Modalities

Whole cell applications are at the forefront in the formulation and delivery of novel therapeutic modalities. These new applications include cultivated meat, and therapeutics based on stem cells, cell therapy, exosomes and T cells.